Literature DB >> 837966

Carbamazepine and its 10,11-epoxide in children and adults with epilepsy.

S Pynnönen, M Sillanpää, H Frey, E Iisalo.   

Abstract

The plasma concentrations of carbamazepine and its 10,11-epoxide were measured in 37 children and 13 adults with epilepsy during maintenance therapy. The children formed relatively more of the epoxy metabolite than adults. The daily dose, expressed as mg/kg or mg/m2, showed a statistically significant correlation with blood level in children, but not in adults. The cerebrospinal fluid concentrations of carbamazepine and carbamazepine-10,11-epoxide in nine children were 33 and 41 per cent, respectively, of the concomitant plasma level.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 837966     DOI: 10.1007/BF00562904

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  Serum concentration of carbamazepine: comparison of Herrmann's spectrophotometric method and a new GLC method for the determination of carbamazepine.

Authors:  S Pynnönen; M Sillanpää; H Frey; E Iisalo
Journal:  Epilepsia       Date:  1976-03       Impact factor: 5.864

2.  Effects of age, sex, obesity, and pregnancy on plasma diphenylhydantoin levels.

Authors:  A L Sherwin; J S Loynd; G W Bock; C D Sokolowski
Journal:  Epilepsia       Date:  1974-12       Impact factor: 5.864

3.  Preliminary observations of serum carbamazepine concentration in epileptic patients.

Authors:  J J Cereghino; J C Meter; J T Brock; J K Penry; L D Smith; B G White
Journal:  Neurology       Date:  1973-04       Impact factor: 9.910

4.  Disappearance of phenobarbital and diphenylhydantoin from serum of children.

Authors:  L K Garrettson; P G Dayton
Journal:  Clin Pharmacol Ther       Date:  1970 Sep-Oct       Impact factor: 6.875

5.  Carbamazepine (Tegretol) as an anticonvulsant. A controlled double-blind comparison with diphenylhydantoin (Dilantin).

Authors:  A S Troupin; J R Green; L M Halpern
Journal:  Acta Neurol Scand Suppl       Date:  1975

Review 6.  Metabolism and Pharmacolinetics of Carbamazepine.

Authors:  P L Morselli; A Frigerio
Journal:  Drug Metab Rev       Date:  1975       Impact factor: 4.518

7.  Drug metabolism in normal children, lead-poisoned children, and normal adults.

Authors:  A P Alvares; S Kapelner; S Sassa; A Kappas
Journal:  Clin Pharmacol Ther       Date:  1975-02       Impact factor: 6.875

8.  Carbamazepine for epilepsy. A controlled prospective evaluation.

Authors:  J J Cereghino; J T Brock; J C Van Meter; J K Penry; L D Smith; B G White
Journal:  Neurology       Date:  1974-05       Impact factor: 9.910

9.  Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses.

Authors:  M Eichelbaum; K Ekbom; L Bertilsson; V A Ringberger; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953

10.  Plasma levels of carbamazepine and carbamazepine-10,11-epoxide during treatment of epilepsy.

Authors:  M Eichelbaum; L Bertilsson; L Lund; L Palmér; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953

View more
  18 in total

Review 1.  Pharmacokinetic considerations in the treatment of childhood epilepsy.

Authors:  Jamie T Gilman; Michael Duchowny; Ana E Campo
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

2.  What is the right dose for children?

Authors:  Massimo Cella; Catherijne Knibbe; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

Review 3.  Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children.

Authors:  Natasa Djordjevic; Slobodan M Jankovic; Jasmina R Milovanovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

4.  Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine 10,11-epoxide in epileptic patients.

Authors:  J J MacKichan; P K Duffner; M E Cohen
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

Review 5.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

6.  Free concentration of carbamazepine and carbamazepine-10,11-epoxide in children and adults. Influence of age and phenobarbitone co-medication.

Authors:  R Riva; M Contin; F Albani; E Perucca; G Procaccianti; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

8.  Dose-dependent pharmacokinetics of carbamazepine in rats: determination of the formation clearance of carbamazepine-10,11-epoxide.

Authors:  R P Remmel; M W Sinz; J C Cloyd
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

Review 9.  Clinical pharmacokinetics of carbamazepine.

Authors:  L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

10.  Effects of josamycin on carbamazepine kinetics.

Authors:  G Vinçon; H Albin; F Demotes-Mainard; M Guyot; C Bistue; P Loiseau
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.